Sign in
AT

ABEONA THERAPEUTICS INC. (ABEO)·Q3 2025 Earnings Summary

Executive Summary

  • Q3 results reflected a commercial timing shift: first ZEVASKYN patient treatments moved to 4Q 2025 after an FDA‑mandated rapid sterility release assay produced a false positive; assay optimization is complete and biopsies resumed, with management reiterating 2026 launch goals .
  • Revenue was $0.0M vs Wall Street consensus of $5.53M, a significant miss due to the one‑quarter shift; EPS was $(0.10) vs $(0.275) est., a beat, aided by lower R&D, fair value gains, and a tax benefit . S&P Global estimates used for comparisons.*
  • Commercial readiness strengthened: 12 ZEVASKYN Product Order Forms (ZPOFs) in hand, ~30 eligible patients identified, three Qualified Treatment Centers (QTCs) activated, and broad market access (commercial policies covering ~80% of lives; baseline coverage across all 51 Medicaid programs + Puerto Rico as of Oct 1) .
  • CMS assigned a permanent J‑code (J3389) effective Jan 1, 2026, expected to streamline reimbursement; liquidity remains strong with $207.5M cash and investments (~2+ years runway pre‑sales) .

What Went Well and What Went Wrong

  • What Went Well

    • Demand, access, and site readiness improved: “We have strong and growing patient demand… our expanding treatment site network and powerful momentum from the patient and caregiver community” . Commercial payers published policies covering ~80% of lives; Medicaid baseline coverage is in place nationwide plus Puerto Rico .
    • QTC network expanded to three (Lurie, Stanford, Children’s Hospital Colorado) with additional centers onboarding; ~30 eligible patients identified at QTCs and 12 ZPOFs received .
    • Reimbursement infrastructure advanced: “CMS has established a permanent… J‑code for ZEVASKYN, J3389… effective January 1, 2026,” which “will simplify claims and reimbursement processing” .

  • What Went Wrong

    • Manufacturing release assay issue caused a one‑quarter delay in first treatments: a rapid sterility assay (added during BLA review) produced a false positive, forcing lot rejection and a temporary biopsy pause until optimization and regulatory submission were completed .
    • Revenue timing miss vs. consensus ($0.0M vs $5.53M est.) due to the treatment shift; SG&A stepped up to $19.3M with launch build‑out and cost reclassifications post‑approval .
    • Plant maintenance shutdown scheduled mid‑Dec to early Jan (FDA requirement), adding near‑term operational friction as dosing begins .

Financial Results

  • Quarterly trend (oldest → newest)
MetricQ1 2025Q2 2025Q3 2025
Revenues ($USD Millions)$0.00 $0.40 $0.00
Net Income (Loss) ($USD Millions)$(12.03) $108.83 $(5.16)
Basic EPS ($)$(0.24) $2.07 $(0.10)
R&D Expense ($USD Millions)$9.94 $5.94 $4.22
SG&A/G&A Expense ($USD Millions)$9.79 $17.15 $19.31
Change in Fair Value of Warrant/Deriv. ($USD Millions)$7.25 $(5.39) $2.76
Income Tax (Benefit) Expense ($USD Millions)N/A$15.51 $(15.20)
Cash, Cash Equiv., Restricted Cash & ST Inv. ($USD Millions)$84.5 $225.9 $207.5
  • Year-over-year (Q3 2025 vs Q3 2024)
MetricQ3 2024Q3 2025
R&D Expense ($USD Millions)$8.94 $4.22
SG&A Expense ($USD Millions)$6.40 $19.31
Net Income (Loss) ($USD Millions)$(30.27) $(5.16)
Basic EPS ($)$(0.63) $(0.10)
  • Versus S&P Global consensus (Q3 2025)
MetricActualConsensusSurprise
Revenue ($USD Millions)$0.00 $5.53*-$5.53
EPS (Primary/Basic per share)$(0.10) $(0.275)*+$0.175

Values marked with * are retrieved from S&P Global.

Notes:

  • Q2 net income included a one‑time $152.37M gain from PRV sale, distorting sequential comparisons .

  • Q3 revenue was $0 as first treatments slipped into 4Q; SG&A rose with commercial buildout and reclassifications post‑approval .

  • Segment breakdown: Not applicable (single therapy launch) .

  • Operational KPIs (oldest → newest)

KPIQ1 2025Q2 2025Q3 2025
QTCs Activated1 (Lurie Children’s) 2 (Lurie, Stanford) 3 (adds Children’s Hospital Colorado)
Identified Eligible Patients at QTCs~30 patient registrations via Abeona Assist (broader) >12 identified at first 2 QTCs ~30 identified at QTCs
ZEVASKYN Product Order Forms (ZPOFs)N/AN/A12 ZPOFs received
Commercial CoverageValue‑based agreements with groups covering ~100M lives Multiple national/regional payers; UHC policy to label Policies published by major payers; ~80% of commercial lives; ~60% of RDEB patients covered
Medicaid CoverageIn progress NDRA executed with CMS to facilitate state coverage Baseline coverage across all 51 state programs + Puerto Rico (effective Oct 1, 2025)
J‑Code——J3389 effective Jan 1, 2026

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
First Commercial Patient Treatment20253Q 2025 (Q2 PR) 4Q 2025 (Q3 PR/call) Delayed one quarter
Profitability Timing20261H 2026 (Q1 PR) 1H 2026 reiterated; delay not expected to impact timing (Q3 Q&A) Maintained
Monthly Capacity RampMid‑2026Up to 10 patients/month by mid‑2026 (Q2 PR) Reiterated/No change (Q3 materials) Maintained
QTC Network20255 QTCs by YE 2025 (Q1 PR) 3 active; several onboarding (Q3 PR) In progress
Reimbursement Coding2026—Permanent J‑code (J3389) effective Jan 1, 2026 New positive development

Earnings Call Themes & Trends

TopicPrevious Mentions (Q1–Q2 2025)Current Period (Q3 2025)Trend
Manufacturing/QualityPost‑approval scale‑up; no release assay issue disclosed Rapid sterility release assay false positive caused lot rejection; assay optimized; biopsies resumed; treatments anticipated in 4Q 2025 Temporary setback resolved; trajectory improving
Patient Demand FunnelEarly registrations (~30); strong interest >12 identified at first two QTCs (Q2) ~30 eligible at QTCs; 12 ZPOFs in process
Market AccessValue‑based deals; UHC policy to label (no wound size restriction) Policies from major payers; ~80% commercial lives; Medicaid baseline nationwide; J‑code effective 1/1/26 Improving
QTC Network1→2 active QTCs; more in 2025 3 active QTCs; more onboarding Expanding
Profitability ViewEarly 2026/1H 2026 path framed 1H 2026 reiterated despite delay Unchanged
Operations/Plant——Planned shutdown mid‑Dec to early Jan for maintenance (FDA requirement)
Competitive Context——Many patients likely on Vyjuvek/Filsuvez; could aid documentation for payers

Management Commentary

  • “We are scaling the ZEVASKYN launch to meet patient needs… Despite a one‑quarter shift in patient starts, we remain steadfast in our 2026 launch goals.” — Vish Seshadri, CEO .
  • “Policies covering ZEVASKYN have been published by all major commercial payers… covering 80% of lives… CMS has established a permanent… J‑code… effective January 1, 2026.” — Company statement .
  • “These patients… we have already received ZPOFs for 12 patients… demand… has now more than doubled to approximately 30 patients.” — Chief Commercial Officer .
  • “We do not see a significant impact… in the first half of 2026, we should be a profitable business… that continues to be our projection.” — Management in Q&A .
  • “Revenue is recognized when the product is applied on the patient.” — Management clarification .

Q&A Highlights

  • Conversion and timing from ZPOF to treatment: Multiple patients already have prior auth; biopsies resumed; timing expected to normalize as processes mature; conversion expected to be high given motivation and clinical success rates to date .
  • Profitability unchanged: Despite the Q3→Q4 shift for first treatment, 1H 2026 profitability timeline maintained .
  • Operations cadence: Facility maintenance shutdown mid‑Dec to early Jan (FDA requirement) noted for planning .
  • Prior authorization dynamics: Many payers aligning to label (e.g., UHC); minimal step edits; denials for age mismatches can be overturned with medical necessity letters .
  • Revenue recognition: Recognized on day of administration; cash collection follows site trade terms .
  • Competitive backdrop: Many patients likely on Vyjuvek/Filsuvez, which can facilitate payer documentation; exact counts not disclosed .

Estimates Context

  • Q3 2025 results vs. S&P Global consensus: Revenue $0.0M vs $5.53M* (miss), EPS $(0.10) vs $(0.275)* (beat). Number of estimates: EPS (6), Revenue (7).
    Values marked with * are retrieved from S&P Global.

Where estimates may adjust:

  • Near‑term revenue estimates likely to be re‑timed into 4Q 2025/1Q 2026 given the documented assay‑related shift and maintenance window .
  • Expense phasing reflects commercialization (SG&A elevation, R&D downshift due to capitalization/reclassification), which should inform opex run‑rate models .

Key Takeaways for Investors

  • The revenue miss was timing‑driven by a resolved release assay issue; first treatments now expected in 4Q 2025, setting up initial revenue recognition ahead of a fuller 2026 ramp .
  • EPS beat despite zero revenue underscores cost discipline, fair value gains, and a tax benefit; however, SG&A is structurally higher with the launch buildout .
  • Commercial infrastructure is de‑risking: 12 ZPOFs, ~30 eligible patients identified at QTCs, three active QTCs, nationwide Medicaid baseline, and a permanent J‑code effective Jan 1, 2026 .
  • Profitability timeline (1H 2026) reaffirmed; investors should monitor treatment starts cadence exiting the maintenance shutdown window and conversion from ZPOF to dosing .
  • The PRV windfall makes sequential compares noisy; focus on operational KPIs (ZPOFs, payer policies, QTC activations) as leading indicators of the 2026 revenue curve .
  • Competitive overlap (Vyjuvek/Filsuvez) may aid access documentation rather than impede adoption, per management; watch for real‑world differentiation as dosing begins .
  • Pipeline optionality (ABO‑503 selected for FDA RDEA pilot) adds medium‑term value creation beyond ZEVASKYN .

Footnote: S&P Global consensus estimates used for comparison of revenue and EPS.*